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OBJECTIVES The aim of this study was to examine the characteristics of non-sustained ventricular
tachycardia (NSVT) episodes during Holter monitoring and to determine their relationship
to age and prognosis.
BACKGROUND It has been suggested that NSVT is only of prognostic importance in patients with
hypertrophic cardiomyopathy (HCM) when repetitive, prolonged, or associated with symp-
toms.
METHODS We studied 531 patients with HCM (323 male, 39  15 years). All underwent ambulatory
electrocardiogram monitoring (41  11 h).
RESULTS A total of 104 patients (19.6%) had NSVT. The proportion of patients with NSVT increased
with age (p 0.008). Maximum left ventricular wall thickness and left atrial size were greater
in patients with NSVT. Mean follow-up was 70  40 months. Sixty-eight patients died, 32
from sudden cardiac death (SCD). Twenty-one patients received an implantable cardioverter
defibrillator (ICD). There were four appropriate ICD discharges. In patients 30 years (but
not 30), five-year freedom from sudden death was lower in those with NSVT (77.6% [95%
confidence interval (CI): 59.8 to 95.4] vs. 94.1% [95% CI: 90.2 to 98.0]; p  0.003). There
was no relation between the duration, frequency, or rate of NSVT runs and prognosis at any
age. The odds ratio of sudden death in patients 30 years of age with NSVT was 4.35 (95%
CI: 1.54 to 12.28; p 0.006) compared with 2.16 (95% CI: 0.82 to 5.69; p 0.1) in patients
30 years of age.
CONCLUSIONS Non-sustained ventricular tachycardia is associated with a substantial increase in sudden
death risk in young patients with HCM. A relation between the frequency, duration, and rate
of NSVT episodes could not be demonstrated. (J Am Coll Cardiol 2003;42:873–9) © 2003
by the American College of Cardiology Foundation
Although a number of studies have reported an association
between non-sustained ventricular tachycardia (NSVT) and
the risk of SCD in patients with hypertrophic cardiomyop-
athy (HCM) (1–4), its utility as a clinical risk marker
remains controversial. Most recently, it has been suggested
that NSVT is of prognostic importance only when repeti-
tive, prolonged, or associated with symptoms (5,6). In order
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to test this hypothesis, we studied the relation between the
characteristics of NSVT detected during Holter monitoring
and prognosis in a large single-center population studied
over a period of 13 years.
METHODS
Clinical characterization. A total of 630 consecutive pa-
tients (37  16 years, 382 male) with HCM were assessed
at St. George’s Hospital, London, U.K., between 1988 and
2000 (3,4). The reasons for referral were clinical manage-
ment (37.8%), family screening (25.3%), risk stratification
(23.8%), and diagnosis clarification (13.2%). The diagnosis
of HCM was based on the presence of unexplained left
ventricular (LV) hypertrophy more than two standard de-
viations from normal ranges corrected for age and body size,
or on the presence of unexplained electrocardiographic and
echocardiographic abnormalities in relatives of patients with
unequivocal disease (7,8). Patients in this study were se-
lected from the cohort of 630 patients using the following
criteria: 1) age 14 to 75 years; 2) follow-up for more than
one day; and 3) successful completion of Holter monitoring.
A detailed family pedigree and clinical history were ob-
tained from all patients. A history of syncope was defined as
one or more episodes of unexplained loss of consciousness
within the 12 months preceding the first visit to St.
George’s Hospital. Chest pain was classified as exertional,
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or atypical if it occurred at rest and/or lasted more than 30
min at rest in the absence of myocardial infarction. The
New York Heart Association classification was used to
grade dyspnea. A family history of sudden death was defined
as SCD in two or more first-degree relatives 40 years of
age.
Electrocardiography. Two-channel (CM1 on channel 1
and V2 on channel 2) 24 to 48 h (mean, 41  11 h)
ambulatory electrocardiogram monitoring was performed in
all patients (Marquette Electronics, Milwaukee, Wiscon-
sin). Non-sustained ventricular tachycardia was defined as
three or more consecutive ventricular beats at a rate of120
beats/min, lasting for 30 s. One investigator (L.M.)
reviewed all the studies, identifying and printing all episodes
of NSVT on 25 mm/s speed paper, including the three beats
immediately preceding each episode. The same investigator
(L.M.), unaware of the clinical, echocardiographic, and
follow-up data, made the following measurements for each
episode of NSVT: 1) number of consecutive ventricular
beats; 2) rate of the VT; and 3) the number of runs during
each recording.
Echocardiography. Two-dimensional and M-mode echo-
cardiography were performed using standard methods (9).
In brief, end-diastolic LV wall thickness was recorded at
mitral valve and papillary muscle level in the anterior and
posterior septum, and in the lateral and posterior LV wall
using short-axis two-dimensional images. Anterior and
posterior wall thickness at the apex was measured in the
two-chamber and short-axis apical views. Left ventricular
outflow tract velocities were measured using continuous-
wave Doppler, and LV outflow tract gradients were calcu-
lated using the modified Bernouilli equation (LV outflow
tract gradient  4  [LV outflow tract velocity]2).
Exercise testing. Patients were exercised to exhaustion on
a treadmill using the Bruce or modified Bruce protocols
(1988 to 1994), or on an upright bicycle ergometer (Sen-
sormedics ergometrics 800S, Bitz, Germany) using an
incremental ramp protocol (1994 onwards). Blood pressure
was measured by auscultation of the brachial artery during
deflation of a mercury sphygmomanometer at rest, every
minute during exercise and for the first 5 min of recovery.
Blood pressure response to exercise was considered abnor-
mal when systolic blood pressure failed to increase by more
than 25 mm Hg from baseline, or when there was a decrease
of more than 10 mm Hg from the maximum blood pressure
during exercise (3,10).
Survival analysis. Follow-up started with the date of the
initial Holter recorded at St. George’s Hospital. Survival
data were collected in routine clinic visits and where
necessary by direct communication with patients and their
attending physicians. Additional information was obtained
using a written questionnaire sent to all patients’ general
practitioners. In order to assess the influence of amiodarone
on the relation between NSVT and prognosis, patients who
had received the drug for the majority (50%) of their
follow-up were compared with patients who had never
taken the drug or who had received the drug for 50% of
their follow-up period.
As previously described (3,4), for the end point classifi-
cation, we considered sudden death a witnessed death
within 1 h of new symptoms and nocturnal deaths with no
antecedent history of worsening symptoms. Deaths pre-
ceded by new signs and/or symptoms of heart failure of
more than 1 h duration and/or cardiogenic shock were
considered as heart failure deaths. Deaths secondary to
stroke, pulmonary or systemic embolism, or myocardial
infarction were also considered as cardiovascular deaths.
Statistical analysis. SPSS for PC statistical program
(SPSS Inc., Chicago, Illinois) was used for the analysis.
Continuous variables are presented as mean  SD. Student
t test (paired or unpaired) was used to compare continuous
variables in patients with and without NSVT. Mann-
Whitney U test was used to compare NSVT characteristics
in patients with and without events. Chi-square test was
used to compare categorical variables. Log-rank test was
used to compare survival curves from different groups. A
multivariate Cox regression model was used to analyze the
relation between NSVT and survival. A p value 0.05 was
considered statistically significant.
RESULTS
Clinical characteristics. From a total of 630 patients
assessed between 1988 and 2000, 531 patients (39  15
years, 323 male) fulfilled the selection criteria. Exclusions
comprised 31 patients younger than 14, three patients older
than 75, nine patients without follow-up data, and 56
patients with insufficient Holter data to permit analysis of
NSVT characteristics. The mean age at Holter was 39 15
years. Fifty-four patients (10%) were 20 years old, 109
(20%) were age 20 to 29, 114 (21%) were between 30 and
39, 121 (23%) were age 40 to 49, and 82 (15%) were
between 50 and 59. Fifty-one (10%) patients were age 60 to
75. Symptoms at initial assessment and the results of
noninvasive testing in the study cohort of 531 patients are
shown in Table 1.
NSVT characteristics. RELATION TO CLINICAL FEA-
TURES. A total of 104 patients (19.6%) had NSVT during
their initial Holter recording. The proportion of patients
with NSVT at their first Holter increased with age (p 
0.008) (Fig. 1). The youngest patient with NSVT was 17
years old. Maximum LV wall thickness and left atrial size
Abbreviations and Acronyms
CI  confidence interval
HCM  hypertrophic cardiomyopathy
ICD  implantable cardioverter defibrillator
LV  left ventricular
NSVT  non-sustained ventricular tachycardia
SCD  sudden cardiac death
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were greater in patients with NSVT: 22.6  5.9 mm versus
20.3 6.8 mm (p 0.001) and 45.6 8.3 mm versus 41.8
 8.2 mm (p  0.0001), respectively. Non-sustained
ventricular tachycardia was more frequent in patients with
atrial fibrillation (38% of patients with NSVT vs. 19% in
patients in sinus rhythm; p  0.046).
NUMBER AND RATE OF RUNS. The median number of runs
of NSVT in 48 h was one (mean, 3.3  8; range, 1 to 69).
A total of 88% of the patients with NSVT had four or less
runs in 48 h (Fig. 2). The mean maximum rate of the NSVT
runs was 157  26 beats/min (range, 120 to 240), and the
mean rate of all the runs was 150  22 beats/min (range,
120 to 222). The mean number of beats of the longest run
was 6.3  4 beats (range, 3 to 29; median, 5 beats) and of
all runs 4.7  2 (range, 3 to 15; median, 4). There was a
correlation between LV end-systolic diameter and the
number of beats of the longest run of NSVT (r  0.267, p
 0.02). No other significant relation was detected between
NSVT characteristics and echocardiographic features or
age.
Follow-up. Mean follow-up was 70 40 months (one day
to 160 months). There were 68 deaths in the 531 study
patients. Thirty-two patients died suddenly, eight patients
Table 1. Clinical and Echocardiographic Characteristics of Patients With and Without NSVT
Total
(n  531)
No NSVT
(n  427)
NSVT
(n  104) p Value
Age at Holter (yrs) 39  15 (14–75) 38  15 (14–75) 43  14 (14–75) 0.006
Male/female 323/208 256/171 67/37 0.4
Syncope 97 (18) 77 (18) 20 (19) 0.8
FHSD 137 (26) 115 (27) 22 (21) 0.3
Chest pain
Exertional 168 (32) 135 (32) 33 (32) 1
Atypical 53 (10) 48 (11) 5 (5) 0.07
NYHA
Class I 317 (60) 257 (60) 60 (58) 1
Class II 192 (36) 151 (35) 41 (39) 1
Class III/IV 19 (4) 16 (4) 3 (3) 1
ABPR 155 (29) 123 (29) 32 (31) 1
AF 21 (4) 13 (3) 8 (8) 0.045
MLVWT (mm) 20.7  6.7 (8–43) 20.3  6.8 (8–43) 22.6  5.9 (12–39) 0.001
LVED (mm) 43.8  6 (19–68) 43.7  6 (22–67) 44.4  7 (24–65) 0.4
LVES (mm) 25.2  7 (10–58) 25  6 (10–58) 26  8 (10–49) 0.3
LA (mm) 42.6  8.3 (19–68) 41.8  8.2 (19–63) 45.6  8.3 (30–68) 0.0001
LVOTO 120 (22) 89 (21) 31 (30) 0.06
Amiodarone 92 (17) 64 (15) 28 (27) 0.006
Beta-blocker 203 (38) 170 (40) 33 (32) 0.1
ICD 21 (4) 18 (4) 3 (3) 0.8
Mean  SD (range) for continuous variables and number (%) for qualitative variables.
ABPR abnormal blood pressure response; AF atrial fibrillation; Amiodarone amiodarone during 50% of the follow-up
or longer; FHSD  family history of sudden death; ICD  implantable cardioverter defibrillator; LA  left atrium diameter
(mm); LVED  left ventricular end-diastolic diameter (mm); LVES  left ventricular end-systolic diameter (mm); LVOTO
 left ventricular outflow tract obstruction (30 mm Hg); MLVWT  maximum left ventricular wall thickness (mm); NSVT
 non-sustained ventricular tachycardia; NYHA  New York Heart Association functional class.
Figure 1. Relation of age to the presence of non-sustained ventricular
tachycardia (NSVT) during Holter monitoring. The incidence of NSVT
increases with age (p  0.008).
Figure 2. Number of runs of non-sustained ventricular tachycardia
(NSVT) in 48 h in 104 patients with hypertrophic cardiomyopathy and
NSVT.
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died with progressive heart failure, and eight patients died
from other disease-related complications. Twenty patients
died from noncardiovascular or unknown causes. In addi-
tion to this, six patients underwent orthotopic cardiac
transplantation, and four patients received an appropriate
implantable cardioverter defibrillator (ICD) discharge.
Five-year cumulative freedom for all-cause mortality, car-
diac transplantation, or appropriate ICD discharge was
88.9% (95% confidence interval [CI]: 85.9 to 91.9).
Treatments and interventional procedures. A total of
168 patients (31.6%) received amiodarone during their
follow-up, and 92 (17.3%) were on amiodarone for 50% of
their follow-up or more. Eleven of these 92 patients died
(three sudden deaths, four cardiovascular cause, four non-
cardiovascular or unknown cause), two received an appro-
priate ICD discharge, and one received a cardiac transplant.
The reasons for amiodarone therapy were supraventricular
tachycardia (including paroxysmal atrial fibrillation), n 26
(28.3%); sudden death prophylaxis, n  40 (43.5%); and
both supraventricular tachycardia and sudden death prophy-
laxis, n  15 (16.3%). In the remaining 11 patients,
amiodarone therapy had been started by referring physicians
before their evaluation at St. George’s Hospital.
Five-year cumulative survival for all-cause mortality,
heart transplantation, or appropriate ICD discharge was
88.3% (95% CI: 85.0 to 91.6) in patients who had never
taken amiodarone or who had taken the drug for 50% of
follow-up and 91.5% (95% CI: 85.4 to 97.6) in patients who
had taken amiodarone for the majority of follow-up (p 
0.6). The corresponding five-year cumulative survival esti-
mates for sudden death were 93.9% (95% CI: 91.4 to 96.4)
and 97.7% (95% CI: 94.6 to 100) (p  0.1).
Myectomy (20 patients, 2 with NSVT), alcohol septal
ablation (14 patients, 4 with NSVT), and dual chamber
pacemaker implantation (36 patients, 8 with NSVT) were
performed in patients with severe LV outflow tract obstruc-
tion for the treatment of severe symptoms refractory to
medical therapy. Thirty patients (7 with NSVT) received a
pacemaker for the treatment of conduction system disease or
chronotropic incompetence. Five patients (2 with NSVT)
underwent mitral valve replacement. An ICD was im-
planted in 21 patients considered to be at high risk for
sudden death: four with previous ventricular fibrillation
(none of them with NSVT on Holter) and 17 with two or
more recognized risk factors of SCD (3 with NSVT on
Holter).
NSVT and mortality. Forty-two (9.8%) of the 427 pa-
tients without NSVT, and 26 (25%) of the 104 patients
with NSVT died (p  0.0001). Of the 32 patients that died
suddenly, thirteen had NSVT (p  0.005). Five-year
cumulative freedom from all-cause mortality, heart trans-
plantation, or appropriate ICD discharge was 90.6%
(95% CI: 87.5 to 93.7) in patients without NSVT and
82.3% (95% CI: 74.3 to 90.3) in those with NSVT (p 
0.001). Five-year cumulative freedom from sudden death
was 95.6% (95% CI: 93.4 to 97.8) in patients without
NSVT and 90.7% (95% CI: 84.4 to 97.0) in patients with
NSVT (p  0.003). The overall relative risk for sudden
death in patients with NSVT was 2.8 (95% CI: 1.4 to
5.6), p  0.005.
Nine of the 13 patients with NSVT who died suddenly
had only one or two episodes in 48 h. The remaining
patients had 6, 9, 31, and 69 episodes. In seven of the 13
patients, there were no more than three or four beats in the
longest run, and only three patients had runs of more than
five beats. There was no significant difference in any NSVT
variable in patients with and without sudden death or
all-cause mortality (Table 2).
All but one of the 13 patients with NSVT that died
suddenly were in New York Heart Association functional
class I or II at diagnosis, and only one had a family history
of sudden death. Four of these 13 patients with NSVT had
reported previous syncopal episodes, and four had an ab-
normal blood pressure response during upright exercise
testing. Three of these 13 patients had a maximal LV wall
thickness 30 mm. In 5 of the 13 patients with NSVT that
died suddenly, there was no other risk factor for sudden
death but the presence of NSVT. Two of them had a LV
outflow tract 90 mm Hg.
Two of the 28 patients with NSVT who received amio-
darone for more than 50% of their follow-up died suddenly
(one having stopped treatment three months before her
death because of side effects), compared with 11 of the 76
patients with NSVT not receiving amiodarone, p  0.5.
Five-year sudden death discharge freedom was 96.3% (95%
CI: 89.2 to 100) in amiodarone-treated patients with NSVT
and 88.4% (95% CI: 80.2 to 96.6) in patients with NSVT
not treated with amiodarone, p  0.2.
Table 2. NSVT Characteristics in Patients With and Without Sudden Death and in Patients
With and Without Death (All-Cause), Transplant, or ICD Discharge
Sudden Death
Death, Transplant, or
ICD Discharge
No Yes p Value* No Yes p Value*
Number of runs (48 h) 2.3  3.2 9.7  19.7 0.5 2.3  3.3 6.1  14.2 0.2
Number of beats longest run 6.6  4.5 4.9  2.3 0.1 6.3  3.4 6.6  6.9 0.2
Rate fastest run 157  31 167  25 0.1 157  32 165  24 0.08
*Mann-Whitney U test.
Abbreviations in Table 1.
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There was 1 sudden death and 2 appropriate ICD
discharges in the 64 patients without NSVT who received
amiodarone for more than 50% of their follow-up, and 18
sudden deaths and two appropriate ICD discharges in the
remaining 363 patients, p  1. In patients without NSVT,
five-year sudden death freedom was 98.3% (95% CI: 95.0 to
100) in amiodarone-treated patients and 95.1% (95% CI:
92.7 to 97.6) in patients not treated with amiodarone for the
majority of follow-up, p  0.2.
Interaction of age, NSVT, and survival. The relative risk
of sudden death in patients with NSVT varied with age,
being highest in those age 30 years. Fifteen of 174
patients age 30 or younger (6 of 26 with NSVT) and 17 of
357 patients older than 30 at the time of Holter monitoring
(7 of 78 with NSVT) died suddenly during follow-up.
Five-year cumulative freedom for sudden death was 91.6%
(95% CI: 87.3 to 95.9) in patients age 30 or younger versus
96.2% (95% CI: 93.8 to 98.6) in patients older than 30 at
Holter (p 0.2). There was no relation between NSVT and
freedom for sudden death in patients older than 30 (five-
year cumulative freedom 96.5% [95% CI: 94.0 to 99.0]
without NSVT and 95.2% [95% CI: 89.9 to 100] with
NSVT; p 0.1). The odds ratio of sudden death in patients
30 years of age with NSVT was 2.16 (95% CI: 0.82 to
5.69; p  0.1). In patients younger than 30, five-year
freedom from sudden death was lower in the NSVT group
(77.6% [95% CI: 60.2 to 95.0] with NSVT vs. 94.1% [95%
CI: 90.2 to 98.0] without NSVT; p  0.003), with an odds
ratio for sudden death in patients with NSVT of 4.35 (95%
CI: 1.54 to 12.28; p  0.006) (Fig. 3).
Twenty-eight of 174 patients age 30 or younger (11 of 26
with NSVT) and 50 of 358 patients older than 30 at the
time of Holter monitoring (15 of 78 with NSVT) died or
received a cardiac transplantation or an appropriate ICD
discharge during follow-up (p  1). Figure 4 presents the
freedom functions from all-cause mortality, cardiac trans-
plantation, or appropriate ICD discharge in patients older
and younger than 30 with and without NSVT. In older
patients there was no significant difference in all-cause
mortality between patients with NSVT (5-year cumulative
freedom 89.8% [95% CI: 82.5 to 97.1]) versus without
NSVT (5-year cumulative freedom 88.9% [84.8 to 93.0]); p
 0.2. In patients younger than 30 years, freedom was lower
in the NSVT group (5-year cumulative freedom 61.3%
[95% CI: 41.1 to 81.5] with NSVT vs. 93.5% [95% CI: 89.4
to 97.6] without NSVT; p  0.0001).
For patients ages 30 or younger at Holter, we introduced
NSVT in a multivariate Cox regression model with other
recognized predictors for sudden death (Table 3). In a
model including all these variables, NSVT with an odds
ratio of 4 (95% CI: 1.3 to 12.8, p 0.02) and wall thickness
30 mm with an odds ratio of 3.5 (95% CI: 1.2 to 10.7, p
 0.03) were the only independent predictors of sudden
death.
DISCUSSION
The identification of patients with HCM who are at risk of
SCD has been challenging because of the relatively low
disease prevalence and the low annual sudden death rates.
Figure 3. Kaplan-Meier survival curves for sudden death in patients older
(A) and younger (B) than 30 with and without non-sustained ventricular
tachycardia (NSVT). Dotted lines  yes; solid lines  no.
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We have previously suggested that patients with multiple
clinical risk markers have an annual risk of dying suddenly
sufficient to consider ICD implantation (3). The use of
NSVT as a risk marker has, however, remained controver-
sial because of conflicting data in the published literature
(1–6). Two studies have demonstrated a significant associ-
ation between NSVT in patients with HCM and sudden
death risk (1,2). In a study of 86 patients, McKenna et al.
(1) found that NSVT was significantly associated with an
increased risk of sudden death during a mean follow-up
period of 2.6 years. In a similar study, Maron et al. (2)
demonstrated that 67% of patients who died suddenly had
NSVT compared with 17% of survivors. In both studies the
majority of patients had fewer than four episodes of NSVT
during the recording period (1,2). Two more recent inde-
pendent studies have, however, failed to demonstrate a
statistically significant association between sudden death
and NSVT, and it has been suggested that the findings in
the earlier studies reflect referral center bias towards symp-
tomatic high-risk patients (5,6). Although factors such as
patient selection, changing diagnostic criteria, and treat-
ment protocols may explain the discrepancy in the literature,
it is of note that the mean age of patients in the more recent
reports was over 40 years of age. The demonstration in this
study that the association between NSVT and sudden death
risk is particularly strong in patients 30 years of age may
provide another explanation for the failure of some studies
to demonstrate statistically significant relations between
NSVT and prognosis.
The explanation for the complex relation between age,
NSVT, and sudden death risk is unclear. In older patients
progressive myocyte loss and fibrosis may account for the
increased incidence of NSVT in this age group. Conversely,
fibrosis and myocyte loss has had less time to develop in
younger patients, and, thus, ventricular arrhythmia at an
early age may be rarer. However, when NSVT is present in
young patients, it probably reflects a more potent arrhyth-
mogenic substrate caused by myocyte disarray, myocardial
ischemia, and abnormal autonomic function (11–13).
The implication of this study is that when NSVT occurs
in isolation in young patients, it may justify prophylactic
therapy to prevent SCD. In contrast, the same arrhythmia
in older patients may not justify therapy when it occurs in
isolation. A limitation to the study is the small sample size
that could account for the lack of significant association
between NSVT and sudden death in the group of more than
30 years, and studies with larger numbers of patients will be
required to evaluate the prognosis value of the presence of
NSVT in this age group.
Figure 4. Kaplan-Meier survival curves for all-cause mortality, heart
transplantation, or appropriate implantable cardioverter defibrillator dis-
charge in patients older (A) and younger (B) than 30 with and without
non-sustained ventricular tachycardia (NSVT). Dotted lines  yes; solid
lines  no.
Table 3. Multivariate Cox Regression Model for Sudden Death
in Patients Age 30 or Younger at Holter
Variables Odds Ratio 95% CI p Value
NSVT 4.0 1.3–12.8 0.02
MLVWT  30 mm 3.5 1.2–10.7 0.03
ABPR 0.5 0.2–1.7 0.3
FHSD 1.4 0.5–4.5 0.5
Previous syncope 1.3 0.4–4.3 0.7
ABPR  abnormal blood pressure response; CI  confidence interval; FHSD 
family history of sudden cardiac death; MLVWT  maximal left ventricular wall
thickness; NSVT  non-sustained ventricular tachycardia.
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Although the association between sudden death risk and
NSVT in young patients is striking, it should be borne in
mind that the majority of sudden deaths, even in young
patients, occurred in patients without NSVT. In other
words, Holter monitoring identifies only one subset of
young patients at high risk, and other recognized risk factors
need to be excluded in order to reassure individual patients
(14). The infrequent occurrence of symptomatic or sus-
tained ventricular tachycardia during Holter monitoring in
this study means that we were unable to make any comment
on their prognostic importance. However, data from other
studies suggest that prolonged runs of symptomatic ventric-
ular tachycardia are prognostically important in patients
with HCM (15). When long multiple episodes of NSVT
are present, further investigations to exclude coronary artery
disease and to identify possible underlying mechanisms such
as LV apical aneurysms are warranted (15,16).
Conclusions. Non-sustained ventricular tachycardia is as-
sociated with a substantial increase in all-cause mortality
and sudden death risk in young patients with HCM. This
risk is independent of the frequency, duration, and heart
rate of NSVT episodes.
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